Brookstone Capital Management Has $13.42 Million Stock Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Brookstone Capital Management increased its stake in Intuitive Surgical by 15.4% in Q2, holding shares worth approximately $13.42 million.
• Recent transactions by insiders included significant share sales, with Director Amy L. Ladd selling 335 shares and Gary S. Guthart selling 29,360 shares, reducing their holdings substantially.
• Intuitive Surgical reported solid Q3 earnings, with $2.40 EPS beating estimates, and revenue growth of 22.9% year-over-year, prompting positive analyst ratings.

Brookstone Capital Management lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 15.4% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,693 shares of the medical equipment provider's stock after buying an additional 3,304 shares during the period. Brookstone Capital Management's holdings in Intuitive Surgical were worth $13,418,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Chilton Capital Management LLC raised its holdings in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after buying an additional 43 shares in the last quarter. Elite Financial Inc. acquired a new position in shares of Intuitive Surgical during the 1st quarter worth $26,000. LFA Lugano Financial Advisors SA acquired a new position in shares of Intuitive Surgical during the 1st quarter worth $30,000. TD Capital Management LLC raised its holdings in shares of Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock worth $30,000 after buying an additional 45 shares in the last quarter. Finally, 1248 Management LLC acquired a new position in Intuitive Surgical in the 1st quarter worth about $30,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Activity at Intuitive Surgical

In related news, Director Amy L. Ladd sold 335 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $440.69, for a total transaction of $147,631.15. Following the sale, the director owned 739 shares in the company, valued at $325,669.91. This represents a 31.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the sale, the insider owned 19,827 shares in the company, valued at approximately $9,368,059.23. The trade was a 59.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,224 shares of company stock worth $21,716,492 in the last 90 days. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Up 13.9%

NASDAQ ISRG opened at $527.03 on Thursday. The business's 50-day moving average price is $455.28 and its two-hundred day moving average price is $495.80. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The firm has a market capitalization of $188.93 billion, a PE ratio of 69.71, a price-to-earnings-growth ratio of 4.86 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, beating analysts' consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.03% and a net margin of 28.58%.The firm had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the company posted $1.84 EPS. The business's revenue was up 22.9% on a year-over-year basis. As a group, analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Raymond James Financial set a $603.00 target price on Intuitive Surgical and gave the stock an "outperform" rating in a report on Wednesday. UBS Group set a $529.00 target price on Intuitive Surgical in a report on Monday, October 13th. Leerink Partners upped their target price on Intuitive Surgical from $593.00 to $600.00 and gave the stock an "outperform" rating in a report on Wednesday. Royal Bank Of Canada set a $625.00 target price on Intuitive Surgical and gave the stock an "outperform" rating in a report on Wednesday. Finally, Evercore ISI lowered their target price on Intuitive Surgical from $535.00 to $450.00 and set an "in-line" rating for the company in a report on Tuesday, October 7th. Sixteen investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $599.68.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.